Huntington Disease (HD) is a neurodegenerative disorder pathologically characterized by selective degeneration of neurons within the striatum, cortex and hypothalamus. HD is caused by a CAG repeat expansion within the HTT gene, with longer repeats being strongly associated with earlier age-of-onset. Although repeat length explains over half of the variability in age of onset, a landmark genetic study attributed the majority of residual variability to unknown environmental factors. Metal ions with neurotoxic properties are strong candidates for environmental agents that may modulate selective neurodegenerative process like HD because, (1) the differential accumulation of various metals across neuronal subtypes, (2) the similarities between metal ion cytotoxicity and cellular pathways of neurodegeneration, and (3) our research in the previous funding cycle demonstrating altered vulnerability in mouse models of HD to both manganese and cadmium. The long-term goal of this research program is to reveal the pathogenic mechanisms underlying gene-environment interactions in neurodegenerative disease, focusing on HD given its clearly defined genetic etiology, to inform environmental health strategies to delay disease onset or slow the progression of disease. Our highly innovative approach combines (a) a novel high-throughput method to quantify cellular Mn status, (b) a state-of-the-art high throughput screen (HTS) facility at the Vanderbilt Institute of Chemical Biology (VICB), and (c) the clinical relevance of a patient-specific neuronal model system based on human induced pluripotent stem cell (hiPSC) technology.
Aim 1 will test the hypothesis that an HD striatal Mn handling deficit discovered in the previous funding cycle will enable a HTS to find small molecules that mitigate the actions of HD environmental risk factors.
Aim 2 will test the hypothesis that human striatal neuroprogenitors (NPs) from HD patients have increased sensitivity to non-cytotoxic levels of metal toxicants impinging upon specific stress response pathways.
Aim 3 will test the clinical potential of small molecule modifiers of environmental risk factors in HD and whether the magnitude of HD-specific toxicant vulnerability will correlate by patient with established disease-modifiers such as neural lineage specificity, CAG-repeat length and clinical variation in age-of-onset.
These specific aims will reveal disease-relevant environmental stress responses and identify small molecules to mitigate vulnerabilities and restore neuronal homeostasis in HD. Furthermore, discovery of toxicant interactions and patient-specific responses may inform environmental health strategies to delay disease onset or slow the progression of HD using a personalized medicine approach.

Public Health Relevance

The proposed studies will (1) evaluate p53 and AKT/mTOR cell stress signaling pathways as mediators of gene-environment interactions in Huntington disease (HD), (2) test whether human striatal neuroprogenitors derived from HD patients will exhibit selective vulnerability to Mn and other neurotoxicants that impinge upon these specific stress response pathways, (3) validate the pathogenic relevance of these pathways in an in vivo HD mouse model, and (4) determine if patient variation in HD age-of-onset correlates with sensitivity to HD- relevant neurotoxicants. Our multidisciplinary approach seeks to define the functional domains that underlie modulation of HD by environmental risk factors and identify the clinical correlates of the stress response pathways that underlie this neurodegenerative disease.

National Institute of Health (NIH)
National Institute of Environmental Health Sciences (NIEHS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-IFCN-C (02))
Program Officer
Hollander, Jonathan
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Schools of Medicine
United States
Zip Code
Aboud, Asad A; Tidball, Andrew M; Kumar, Kevin K et al. (2015) PARK2 patient neuroprogenitors show increased mitochondrial sensitivity to copper. Neurobiol Dis 73:204-12
Bowman, Aaron B; Aschner, Michael (2014) Considerations on manganese (Mn) treatments for in vitro studies. Neurotoxicology 41:141-2
Kumar, Kevin K; Lowe Jr, Edward W; Aboud, Asad A et al. (2014) Cellular manganese content is developmentally regulated in human dopaminergic neurons. Sci Rep 4:6801
West, James D; Austin, Eric D; Gaskill, Christa et al. (2014) Identification of a common Wnt-associated genetic signature across multiple cell types in pulmonary arterial hypertension. Am J Physiol Cell Physiol 307:C415-30
Kumar, Kevin K; Aboud, Asad A; Patel, Devin K et al. (2013) Optimization of fluorescence assay of cellular manganese status for high throughput screening. J Biochem Mol Toxicol 27:42-9
Madison, Jennifer L; Wegrzynowicz, Michal; Aschner, Michael et al. (2012) Disease-toxicant interactions in manganese exposed Huntington disease mice: early changes in striatal neuron morphology and dopamine metabolism. PLoS One 7:e31024
Xu, Libin; Mirnics, Karoly; Bowman, Aaron B et al. (2012) DHCEO accumulation is a critical mediator of pathophysiology in a Smith-Lemli-Opitz syndrome model. Neurobiol Dis 45:923-9
Kumar, Kevin K; Aboud, Asad A; Bowman, Aaron B (2012) The potential of induced pluripotent stem cells as a translational model for neurotoxicological risk. Neurotoxicology 33:518-29
Wegrzynowicz, Michal; Holt, Hunter K; Friedman, David B et al. (2012) Changes in the striatal proteome of YAC128Q mice exhibit gene-environment interactions between mutant huntingtin and manganese. J Proteome Res 11:1118-32
Bowman, Aaron B; Kwakye, Gunnar F; Herrero Hernandez, Elena et al. (2011) Role of manganese in neurodegenerative diseases. J Trace Elem Med Biol 25:191-203

Showing the most recent 10 out of 15 publications